Clinical Trials Using Gallium Ga 68-labeled PSMA-11

Clinical trials are research studies that involve people. The clinical trials on this list are studying Gallium Ga 68-labeled PSMA-11. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-23 of 23
  • Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET / CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma

    This phase II trial studies how well a positron emission tomography (PET) / computed tomography (CT) scan using fluciclovine F18 compared with a PET / CT scan with gallium Ga 68-labeled PSMA-11 works in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma. Fluciclovine F18 and gallium Ga 68-labeled PSMA-11 are types of tracers, called radiotracers, that are injected and can accumulate in tumor cells to develop images of them during a PET / CT scan. It is not yet known whether giving fluciclovine F18 or gallium Ga 68-labeled PSMA-11 may work better in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma.
    Location: 4 locations

  • A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

    The purpose of this study is to find the highest dose level of study drug, CTT1403, that can be safely administered to patients with metastatic castration resistant prostate cancer (mCRPC).
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • 68Ga-PSMA-11 PET / CT Scan in Detecting Tumor Location and Size in Patients with Prostate Cancer

    This early phase II trial studies how well 68Ga-PSMA-11 positron emission tomography (PET) / computed tomography (CT) scan works in detecting tumor location and size in patients with prostate cancer. 68Ga-PSMA-11 is a radioactive imaging agent that seeks to identify prostate cancer cells that have a specific protein target called prostate-specific membrane antigen on their surface. A 68Ga-PSMA-11 PET / CT scan may help doctors to better detect the location, extent, and characteristics of tumor, allowing improved planning of subsequent therapy.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

  • Gallium Ga 68-labeled PSMA-11 PET / MR in Diagnosing Patients with Recurrent Prostate Cancer

    This phase II trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET) / magnetic resonance (MR) works in diagnosing patients with prostate cancer that has come back. Gallium Ga 68-labeled PSMA-11 may help to show prostate cancer on a PET / MR scan that cannot be seen on other standard imaging even when the PSA levels are very low. It may also help doctors to make decisions about the care.
    Location: 7 locations

  • 68GA-PSMA-11 PET / CT Scan in Impacting Treatment Strategies for Patients with Prostate Cancer

    This phase II trial studies the impact of 68GA-PSMA-11 positron emission tomography (PET) / computed tomography (CT) scan on treatment strategies for patients with prostate cancer. Diagnostic imaging procedures, such as 68GA-PSMA-11 PET / CT scan, may help doctors plan the best treatment for prostate cancer.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Serial PSMA PET Scans for the Imaging of Newly Diagnosed, Progressive, or Metastatic Prostate Cancer

    This phase II / III trial studies how well serial PSMA PET scans work in imaging patients with prostate cancer that is newly diagnosed, growing, spreading, or getting worse (progressive), or has spread to other places in the body (metastatic). PSMA PET scans use radiation to make images of tumors. Serial PSMA PET scans may work better at showing the PSMA protein, which is located on many prostate cancer cells, and in assessing treatment response in patients with prostate cancer compared to the usual imaging methods.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • 68Ga-PSMA-11 and 68Ga-RM2 PET / MRI in Assessing Response in Patients with Prostate Cancer Undergoing HIFU or HDR Therapy

    This phase I / II trial studies how well 68Ga-PSMA-11 and 68Ga-RM2 positron emission tomography (PET) / magnetic resonance imaging (MRI) work in assessing response in patients with prostate cancer who are undergoing high intensity focused ultrasound (HIFU) or high dose rate (HDR) local therapy. Diagnostic procedures, such as 68Ga-PSMA-11 PET / MRI and 68Ga-RM2 PET / MRI, may help measure a patient's response to earlier treatment. This study is being done to see if the combination of imaging agents 68Ga-PSMA-11 and 68Ga-RM2 work better at assessing response to therapy compared to standard imaging or biopsy.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • 68Ga-PSMA PET in Diagnosing Metastasis in Patients with Ovarian Cancer

    This trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 (68Ga-PSMA) positron emission tomography (PET) works in patients with ovarian cancer to detect whether the tumor has spread to other places in the body. 68Ga-PSMA is a radioactive substance that binds to blood vessels around the ovarian cancer and can be imaged using PET. Diagnostic procedures, such as PET, may help find and diagnose find out how far the disease has spread.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • An Investigational Scan (68Ga PSMA-HBED-CC PET / CT Scan) in Imaging Patients with Biochemical Recurrence of Prostate Cancer

    This phase IIb / III trial studies how well 68Ga PSMA-HBED-CC positron emission tomography (PET) / computed tomography (CT) scan works in imaging patients with prostate cancer that is suspected to have come back based on elevated levels of prostate specific antigen but might not be causing disease-related symptoms (biochemical recurrence). Diagnostic procedures, such as 68Ga PSMA-HBED-CC PET / CT, may help find and diagnose prostate cancer.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • 68Ga-RM2 PET / MRI Scan and 68Ga-RM2 PET / MRI Scan in Imaging Patients with Suspected Prostate Cancer

    This phase II trial studies how well 68Ga-PSMA-11 positron emission tomography (PET) / magnetic resonance imaging (MRI) scan and 68Ga-RM2 PET / MRI scan work in imaging patients with suspected prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET / MRI scan and 68Ga-RM2 PET / MRI scan, may help find and diagnose prostate cancer.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • Gallium Ga 68-labeled PSMA-11 PET in Detecting Prostate Cancer Metastasis

    This phase III trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET) works in detecting prostate cancer that has spread to other places in the body. PSMA is a protein found on most prostate cancers. Gallium Ga 68-labeled PSMA-11 is an imaging agent that binds to prostate cancer cells and can be imaged using PET scan. A PET scan uses a special camera to detect energy given off from radioactive material to make detailed pictures of areas where the Ga-68 accumulates in the body. The PET scan if often combined with a magnetic resonance imaging (MRI) or computed tomography (CT) scan may help to more accurately map the location of where in the body the radioactive material has collected. Gallium Ga 68-labeled PSMA-11 may help to detect the presence of prostate cancer that has spread to other places in the body (metastasis).
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • 68GA-PSMA Fusion PET / MRI in Diagnosing Patients with Prostate Cancer

    This phase II trial studies how well 68GA-PSMA fusion PET / MRI works in finding prostate lesions in patients with prostate cancer. Radioactive drugs, such as 68GA-PSMA, are taken up by cancer cells. Diagnostic procedures, such as PET or MRI, may help find and diagnose prostate cancer or find out how far the disease has spread. Giving 68GA-PSMA fusion PET / MRI may work better in diagnosing patients with prostate cancer.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • 68Ga-PSMA-11 PET / CT in Diagnosing Participants with Recurrent Prostate Cancer After Radical Prostatectomy

    This phase III trial studies how well Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET) / computed tomography (CT) works in diagnosing participants with prostate cancer that has come back after surgery. 68Ga-PSMA-11 are taken up by cancer cells. Diagnostic procedures, such as PET / CT scans, may help find and diagnose prostate cancer and find out how far the disease has spread. Giving 68Ga-PSMA-11 with PET / CT may help doctors plan better for salvage radiation therapy in participants with recurrent prostate cancer.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients with Thyroid Cancer

    This phase II trial studies how well Gallium-68 prostate specific membrane antigen positron emission tomography (PET) work in diagnosing patients with thyroid cancer. Diagnostic procedures, such as 68Ga-PSMA PET, may more accurately diagnose thyroid cancer and find out how far the disease has spread.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Gallium Ga 68-labeled PSMA-11 PET / CT in Diagnosing Participants with Biochemical Recurrent Prostate Cancer

    This phase II trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET) / computed tomography (CT) works in diagnosing patients with prostate cancer and with rising prostate specific antigen after treatment. Ga-68 PSMA is an imaging drug that binds to prostate tumor cells and can be imaged using PET. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET / CT, may help find the presence of prostate cancer.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Gallium Ga 68-labeled PSMA-11 PET / CT in Diagnosing Participants with Intermediate to High-Risk Prostate Cancer

    This pilot phase II / III trial studies how well gallium Ga 68-labeled PSMA-11 positron emission tomography / computed tomography (PET / CT) works in diagnosing participants with intermediate to high-risk prostate cancer. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET / CT, may help detect pelvic nodal disease in participants with prostate cancer.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • 68Ga-PSMA-11 PET / CT in Imaging Patients with Intermediate or High Risk Prostate Cancer before Surgery

    This clinical trial studies how well 68Ga-PSMA-11 positron emission tomography (PET) / computed tomography (CT) works in imaging patients with intermediate or high risk prostate cancer before surgery. Diagnostic procedures, such as PET / CT scans, may help find and diagnose prostate cancer and find out how far the disease has spread.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Gallium Ga 68-labeled PSMA-11 PET / CT or PET / MRI in Diagnosing Patients with Biomedical Recurrent Prostate Cancer

    This phase III trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET) / computed tomography (CT) or PET / magnetic resonance imaging (MRI) works in diagnosing patients with prostate cancer and with rising prostate specific antigen after treatment. Ga-68 PSMA is an imaging drug that binds to prostate tumor cells and can be imaged using PET. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET / CT or PET / MRI, may help find the presence of prostate cancer.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Gallium Ga 68-labeled PSMA-11 PET / MRI in Diagnosing Participants with PSMA-positive Tumors

    This pilot trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron-emission tomography (PET) / magnetic resonance imaging (MRI) works in diagnosing participants with PSMA-positive tumors. Gallium Ga 68-labeled PSMA- is an imaging drug that binds to tumor cells and can be imaged using PET / MRI. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET / MRI, may help find the presence of cancer.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • 68Ga PSMA-HBED-CC PET / CT in Imaging Patients with Metastatic Prostate Cancer

    This pilot clinical trial studies how well 68Ga PSMA-HBED-CC positron emission tomography / computed tomography (PET / CT) works in imaging patients with prostate cancer that has spread to other parts of the body. Diagnostic procedures, such as 68Ga PSMA-HBED-CC PET / CT, may help find and diagnose metastatic prostate cancer and find out how far the disease has spread.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Gallium Ga 68-labeled PSMA-11 PET / CT in Detecting Recurrent Prostate Cancer in Patients after Initial Therapy

    This clinical trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET) / computed tomography (CT) works in detecting prostate cancer that has come back in patients after initial therapy. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET / CT, may help doctors detect tumors that have come back after initial therapy.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • 68Ga-PSMA PET / MRI in Finding Tumors in Patients with Intermediate or High-Risk Prostate Cancer Undergoing Surgery

    This phase II / III trial studies gallium 68 Ga (68Ga)-prostate-specific membrane antigen (PSMA) positron emission tomography / magnetic resonance imaging (PET / MRI) in finding tumors in patients with prostate cancer undergoing surgery that tend to spread quickly (intermediate-risk) or is likely to come back or spread (high-risk). Diagnostic procedures, such as PET / MRI, may help find and diagnose prostate cancer and find out how far the disease has spread. Radioactive drugs, such as gallium Ga 68-PSMA, binds to tumor cells that have specific receptors, and may allow doctors to see smaller tumors than the standard of care contrast-enhanced computed tomography (CT) or MRI scan.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • Gallium Ga 68-labeled PSMA-11 PET / CT in Detecting Prostate Cancer Recurrence in Patients with Elevated PSA after Initial Treatment

    This phase II / III trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET) / computed tomography (CT) works in detecting prostate cancer that may have come back in patients with elevated prostate-specific antigen (PSA) after initial treatment. A rise in blood level of PSA, a protein made by the prostate, after treatment with surgery or radiation in patients without symptoms indicates that the cancer may have come back (recurrence). PSA however cannot determine whether the disease is located only in the prostate or other places in the body. 68Ga-PSMA-11 is a radioactive tracer that targets and specifically binds to tumor cells expressing PSA making them lighting up. PET and CT make computerizing pictures of areas inside the body where the radioactive substance is lighting up. 68Ga-PSMA-11 PET / CT may be able to see smaller tumors than standard imaging and may help determine whether prostate cancer has come back and where it is in the body.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California